This is a routine director sale of shares acquired through equity compensation. The small size relative to market cap suggests no material insider concern. Monitor for any subsequent Form 4 filings to confirm execution and for any pattern of larger insider selling.
LGND drugs
LGND drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $308.79entry
- T+1 · 19h ago −2.29%α −0.38% · $301.71
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Martine Zimmermann filed a Form 144 notice of intent to sell 2,000 shares of Ligand Pharmaceuticals common stock, with an estimated aggregate market value of approximately $636,336. The shares were acquired through restricted stock grants in 2025 and 2026. This is a routine insider sale by a director and represents a small fraction of the company's market cap.
Key Facts
- Reporting person: Martine Zimmermann, Director of Ligand Pharmaceuticals
- Securities to be sold: 2,000 shares of Common Stock
- Estimated aggregate market value: $636,336.20
- Shares acquired via restricted stock grants on 06/06/2025 (626 shares), 09/22/2025 (647 shares), and 06/05/2026 (727 shares)
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
- Proposed sale date: 11/12/2026
- Exchange: NASDAQ
Financial Impact
Sale of 2,000 shares valued at approximately $636,336, representing a small fraction of the company's market cap.
Risk Factors
- Insider sale may signal reduced conviction, though the small size and director role limit concern.
- Form 144 is an intent to sell; the actual sale may not occur.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-011042 |
| Document: 0001950047-26-011042-index.html | 0001950047-26-011042 |
| Document: 0001950047-26-011042.txt | 0001950047-26-011042 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers